A Food and Drug Administration advisory panel rejected an effort by Pfizer Inc. to remove boxed warnings of neuropsychiatric dangers on the label for Chantix, the companyâ€™s smoking-cessation drug.. The committee vote was 11 in favor of retaining existing warnings, with six suggesting modifications and one in favor of removal. Several panel members suggested adding sleep disturbances to the warnings. . The...
  